EditorialKenneth Frazier, left, chief executive of Merck & Co., joined by to his right, Albert Bourla, chief executive of Pfizer, and Olivier Brandicourt, chief executive of Sanofi, testifies at a Senate Finance Committee hearing on drug pricing, on Capitol Hill in Washington, Feb. 26, 2019. (Erin Schaff/The New York Times)